To support the implementation of outside the box proof of concept ideas that disrupt long held assumptions/myths about men and their health which will encourage doing things differently and ultimately lead to improved health outcomes.

To support transformational prostate cancer research that will accelerate progress towards the reduction of death and suffering due to recurrent or advanced prostate cancer.

To trial a national program of Prostate Cancer Specialist Nurses working within the hospital system to provide supportive care for men affected by prostate cancer.

To make discoveries which will improve the length and quality of life of men with prostate cancer, especially prostate cancer which cannot be cured by surgery or radiation therapy.

This project sought to establish guidelines and identify key attributes for providers and registry leaders to consider when selecting an electronic tool for collecting data directly from patients regarding their health (i.e. patient-reported outcomes PROMs), to develop a decision framework for selecting the right tool for a given setting and/or context, and summarize information on the most popular tools to facilitate comparison and selection.

To reduce the impact of cancer in the community and improve outcomes for people affected by cancer.To work collaboratively with organisations that support cancer research to generate evidence, increase knowledge, and improve the translation of research into policy and practice.

To define a minimum set of localised prostate cancer health outcome indicators and their measurement to foster research and reporting around the world. The project is looking at the outcomes that matter most to men with localised prostate cancer, and standardising the datapoints and collection method. This will lead to better reporting and research, which will foster changes in practice, improving the outcomes for men who have been diagnosed with localised prostate cancer.

To define a minimum set of health outcome indicators and their measurement that are the most important to collect in the clinic, and in follow up treatment for men who have advanced prostate cancer. Standardising this and the collection method will lead to better reporting and research, which will foster changes in practice, improving the outcomes for men who have been diagnosed with advanced disease.

To train a new generation of researchers with expertise in bioinformatics and prostate cancer in order to make most benefit from new big data sources. We will do this by funding PhD studentships, embedding those students within top prostate research groups with expertise in bioinformatics.

Historically, the only way that researchers could develop their scientific and leadership skills between the end of their PhD and the point at which they were ready to establish their own research group has been to take post-doc positions on projects awarded by us and other funders. This route still remains available, however, we believe that there are significant benefits in providing fellowship funding to extremely promising researchers immediately after their PhD studies are completed. These Fellowsh

To reduce the impact of cancer in the community and improve outcomes for people affected by cancer. To work collaboratively with organisations that support cancer research to generate evidence, increase knowledge, and improve the translation of research into policy and practice.

Dr. Thomas Zilli from Geneva University Hospital will conduct an important multi-centre trial which aims to compare two different radiotherapy techniques in nodal-recurrent prostate cancer patients and determine which is more efficient in slowing the progression of their cancer.

This project is investigating whether targeting a particular protein called TRIM24 could serve as a potential therapy for men with castrate resistant prostate cancer. The funded work will be conducted using pre-clinical models has implications for drug development, and if successful could lead to the initiation of clinical trials for men with advanced prostate cancer.

There is an urgent medical need to find drugs that are effective and that are affordable and can be combined with the newer treatment modalities without causing too much toxicity. In this clinical trial, Dr Karim Fizazi’s team will investigate the role of statins and aspirin in the treatment of castrate resistant prostate cancer.

To support the development and trialling of innovative ideas that could lead to creative solutions that increase levels of social connections and feelings of belongingness for men; particularly those who are at greater risk of becoming socially isolated. These include key ‘at risk’ population groups including new fathers, unemployed men, divorced men and men of low socio economic status.

To support the development and trialling of innovative ideas that could lead to creative solutions that increase levels of social connections and feelings of belongingness for men; particularly those who are at greater risk of becoming socially isolated. These include key ‘at risk’ population groups including new fathers, unemployed men, divorced men and men of low socio economic status.